Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998.

Corcept was in 2019 rated amongst the top 10 fastest growing companies in United States. We are committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity, said Ms Kimberly Park, while announcing the partnership with Qualtran. To support this mission, Corcept collaborates with numerous basic scientists and clinical researchers to find better ways to improve patient lives.

Through our collaborations with researchers around the world, more than 30 studies are underway to investigate the potential benefits GR antagonists may have in the treatment of serious and life-threatening diseases driven by cortisol dysregulation.

Kimberly Park, who was earlier the Global Vice President of Customer Strategy and Innovation at Merck & Co, said we are looking forward to initiating joint research studies in India with Qualtran. Ms. Park held leadership positions in marketing, marketing research, manufacturing and sales at GlaxoSmithKline plc. She currently serves on the Board of Besser Company, a global manufacturer of equipment for the building materials industry.